Title |
Complications of regional citrate anticoagulation: accumulation or overload?
|
---|---|
Published in |
Critical Care, November 2017
|
DOI | 10.1186/s13054-017-1880-1 |
Pubmed ID | |
Authors |
Antoine G. Schneider, Didier Journois, Thomas Rimmelé |
Abstract |
Regional citrate anticoagulation (RCA) is now recommended over systemic heparin for continuous renal replacement therapy in patients without contraindications. Its use is likely to increase throughout the world. However, in the absence of citrate blood level monitoring, the diagnosis of citrate accumulation, the most feared complication of RCA, remains relatively complex. It is therefore commonly mistaken with other conditions. This review aims at providing clarifications on RCA-associated acid-base disturbances and their management at the bedside. In particular, the authors wish to propose a clear distinction between citrate accumulation and net citrate overload. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 7 | 13% |
United Kingdom | 6 | 11% |
Argentina | 3 | 6% |
Spain | 3 | 6% |
Portugal | 2 | 4% |
Australia | 2 | 4% |
Malaysia | 2 | 4% |
Canada | 1 | 2% |
Venezuela, Bolivarian Republic of | 1 | 2% |
Other | 6 | 11% |
Unknown | 20 | 38% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 37 | 70% |
Practitioners (doctors, other healthcare professionals) | 11 | 21% |
Scientists | 4 | 8% |
Science communicators (journalists, bloggers, editors) | 1 | 2% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 133 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 28 | 21% |
Researcher | 20 | 15% |
Student > Postgraduate | 11 | 8% |
Professor > Associate Professor | 7 | 5% |
Student > Master | 7 | 5% |
Other | 20 | 15% |
Unknown | 40 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 66 | 50% |
Nursing and Health Professions | 7 | 5% |
Biochemistry, Genetics and Molecular Biology | 4 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
Agricultural and Biological Sciences | 1 | <1% |
Other | 8 | 6% |
Unknown | 45 | 34% |